Overview of the 2022 WHO classification of parathyroid tumors
The 2022 WHO classification reflects increases in the knowledge of the underlying
pathogenesis of parathyroid disease. In addition to the classic characteristic features of …
pathogenesis of parathyroid disease. In addition to the classic characteristic features of …
Biochemical assessment of pheochromocytoma and paraganglioma
G Eisenhofer, C Pamporaki, JWM Lenders - Endocrine reviews, 2023 - academic.oup.com
Pheochromocytoma and paraganglioma (PPGL) require prompt consideration and efficient
diagnosis and treatment to minimize associated morbidity and mortality. Once considered …
diagnosis and treatment to minimize associated morbidity and mortality. Once considered …
Current status of gastrointestinal carcinoids
IM Modlin, M Kidd, I Latich, MN Zikusoka, MD Shapiro - Gastroenterology, 2005 - Elsevier
Gastrointestinal (GI) carcinoids are ill-understood, enigmatic malignancies, which, although
slow growing compared with adenocarcinomas, can behave aggressively. Carcinoids are …
slow growing compared with adenocarcinomas, can behave aggressively. Carcinoids are …
The diagnosis and medical management of advanced neuroendocrine tumors
GA Kaltsas, GM Besser, AB Grossman - Endocrine reviews, 2004 - academic.oup.com
Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that
originate from endocrine glands such as the pituitary, the parathyroids, and the …
originate from endocrine glands such as the pituitary, the parathyroids, and the …
The chromogranin–secretogranin family
L Taupenot, KL Harper… - New England Journal of …, 2003 - Mass Medical Soc
The members of the chromogranin–secretogranin family of peptide hormones, biogenic
amines, and neurotransmitters are enclosed within vesicles in the neuroendocrine system …
amines, and neurotransmitters are enclosed within vesicles in the neuroendocrine system …
Endocrine tumours of the pancreas
K Öberg, B Eriksson - Best practice & research Clinical gastroenterology, 2005 - Elsevier
Endocrine pancreatic tumours (EPTs) are uncommon tumours occurring in approximately 1
in 100 000 of the population, representing 1–2% of all pancreatic neoplasms. Some of the …
in 100 000 of the population, representing 1–2% of all pancreatic neoplasms. Some of the …
Novel biomarkers of cardiovascular disease: applications in clinical practice
MN Lyngbakken, PL Myhre, H Røsjø… - Critical reviews in …, 2019 - Taylor & Francis
Measurement of biomarkers has revolutionized the work-up of patients with suspected
cardiovascular disease. The most widely used contemporary cardiovascular biomarkers are …
cardiovascular disease. The most widely used contemporary cardiovascular biomarkers are …
ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers
K Oberg, A Couvelard, G Delle Fave, D Gross… - …, 2017 - karger.com
Biomarkers have been the mainstay in the diagnosis and follow-up of patients with
neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory …
neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory …
Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the α-subunit of glycoprotein hormones
FRE Nobels, DJ Kwekkeboom… - The Journal of …, 1997 - academic.oup.com
Chromogranin A (CgA) is gaining acceptance as a serum marker of neuroendocrine tumors.
Its specificity in differentiating between neuroendocrine and nonneuroendocrine tumors, its …
Its specificity in differentiating between neuroendocrine and nonneuroendocrine tumors, its …
The chromogranins A and B: the first 25 years and future perspectives
H Winkler, R Fischer-Colbrie - Neuroscience, 1992 - Elsevier
The chromogranins A and B: The first 25 years and future perspectives - ScienceDirect Skip to
main contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View PDF …
main contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View PDF …